UBS Group reiterated their sell rating on shares of Relx (LON:REL) in a report published on Thursday, Stock Target Advisor reports. UBS Group currently has a GBX 1,790 ($23.55) price objective on the stock, up from their prior price objective of GBX 1,725 ($22.69).
REL has been the subject of a number of other reports. HSBC reissued a buy rating on shares of Relx in a research note on Monday, January 13th. Barclays reissued an overweight rating and set a GBX 2,090 ($27.49) target price on shares of Relx in a research note on Friday, October 25th. Berenberg Bank increased their target price on Relx from GBX 1,930 ($25.39) to GBX 2,120 ($27.89) and gave the stock a buy rating in a research note on Wednesday, January 15th. Liberum Capital reissued a buy rating and set a GBX 1,750 ($23.02) target price on shares of Relx in a research note on Thursday, October 24th. Finally, Citigroup raised Relx to a buy rating in a research note on Tuesday, January 21st. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. Relx currently has an average rating of Buy and a consensus target price of GBX 1,944.22 ($25.58).
Shares of LON:REL opened at GBX 2,050 ($26.97) on Thursday. The company has a market capitalization of $39.70 billion and a price-to-earnings ratio of 26.59. The firm’s 50 day simple moving average is GBX 1,913.39 and its 200 day simple moving average is GBX 1,896.57. The company has a debt-to-equity ratio of 308.02, a current ratio of 0.45 and a quick ratio of 0.40. Relx has a fifty-two week low of GBX 1,597 ($21.01) and a fifty-two week high of GBX 2,027 ($26.66).
RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.
Read More: What is a Derivative?
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.